Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Jaguar Health, Inc. (JAGX)
Price$0.5950Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2018
2020
2021
2022
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5M | $11.7M | $9.8M | $12.0M | $4.3M | $9.4M | $5.8M | $4.4M | $4.4M | $141,523 | $258,381 | $0 |
| Gross profit | $7.7M | $9.7M | $7.7M | $9.9M | $2.0M | $6.1M | $2.0M | $1.7M | $3.5M | $89,557 | $134,924 | — |
| Gross margin | 67.21% | 83.27% | 79.13% | 83.11% | 46.18% | 65.05% | 33.92% | 37.37% | 79.81% | 63.28% | 52.22% | — |
| Research & development | $25.0M | $16.5M | $18.6M | $17.6M | $15.1M | $6.4M | $5.8M | $5.2M | $4.3M | $7.2M | $6.5M | $4.2M |
| Operating expenses | $57.4M | $42.5M | $44.1M | $46.4M | $45.0M | $36.0M | $34.7M | $35.2M | $38.6M | $13.7M | $12.7M | $8.3M |
| Operating income | −$45.9M | −$30.8M | −$34.3M | −$34.4M | −$40.7M | −$26.6M | −$28.9M | −$30.8M | −$34.2M | −$13.6M | −$12.4M | −$8.3M |
| Operating margin | −398.82% | −263.76% | −351.31% | −287.85% | −939.05% | −283.93% | −501.26% | −697.98% | −785.27% | −9,599.84% | −4,816.67% | — |
| EBITDA | −$44.0M | −$28.9M | −$32.3M | −$32.4M | −$39.0M | −$24.9M | −$27.2M | −$29.5M | −$33.7M | −$13.5M | −$12.4M | — |
| EBITDA margin | −382.20% | −247.51% | −330.68% | −271.28% | −899.40% | −265.53% | −471.19% | −668.12% | −771.87% | −9,566.28% | −4,814.68% | — |
| Net income | −$53.6M | −$38.5M | −$41.9M | −$48.4M | −$52.6M | −$33.8M | −$38.5M | −$32.1M | −$22.0M | −$14.7M | −$16.3M | −$8.6M |
| Net profit margin | −465.42% | −329.30% | −429.26% | −404.82% | −1,213.38% | −360.25% | −667.34% | −727.92% | −503.73% | −10,410.87% | −6,305.24% | — |
| Basic EPSper basic share | -$719,611.53 | -$4,094,298.25 | -$83,948,644.07 | -$1,696,794,381.16 | -$4,137,401,887.95 | -$10,578,650,489.17 | -$291,746,681,687.96 | -$4,962,931,620.68 | -$16,376,253,708,229,766.00 | -$9,815,875,668,965,175,000.00 | -$19,631,751,337,930,350,000.00 | -$23,558,101,605,516,423,000.00 |
| Diluted EPSper diluted share | -$719,611.53 | -$4,094,298.25 | -$83,948,644.07 | -$1,696,794,381.16 | -$4,137,401,887.95 | -$10,578,650,489.17 | -$291,746,681,687.96 | -$4,962,931,620.68 | -$16,376,253,708,229,766.00 | -$9,815,875,668,965,175,000.00 | -$19,631,751,337,930,350,000.00 | -$23,558,101,605,516,423,000.00 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Lincoln Alternative Strategies LLC | 600K |
CONTE LISA A | 29.26K |
Wolin Jonathan S. | 11.94K |
Chaturvedi Pravin R | 11.94K |
Lizak Carol R. | 11.91K |
King Steven R. | 11.89K |
MICEK JOHN | 7.43K |
Siegel Jonathan B. | 7.42K |
BOCHNOWSKI JAMES J | 6.42K |
Jayasuriya Anula | 5.92K |
UBS Group AG | 4K |
Tower Research Capital LLC (TRC) | 1.16K |
SBI Securities Co., Ltd. | 84 |
BARCLAYS PLC | 56 |
ROYAL BANK OF CANADA | 20 |
WELLS FARGO & COMPANY/MN | 5 |
Leonteq Securities AG | 5 |
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 1 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2025Form 4 | MICEK JOHNDirector | BuyWarrant to Purchase Common Stock · derivative | 9.0K | — | — | 9.0K |
| Mar 31, 2025Form 4 | MICEK JOHNDirector | BuyConvertible Promissory Note · derivative | 9.0K | $50.0K | $450.00M | 9.0K |
| Mar 31, 2025Form 4 | King Steven R.See Remarks | BuyWarrant to Purchase Common Stock · derivative | 3.6K | — | — | 3.6K |
| Mar 31, 2025Form 4 | King Steven R.See Remarks | BuyConvertible Promissory Note · derivative | 3.6K | $20.0K | $72.00M | 3.6K |
| Mar 31, 2025Form 4 | Siegel Jonathan B.Director | BuyWarrant to Purchase Common Stock · derivative · indirect | 9.0K | — | — | 9.0K |